-
公开(公告)号：US20110086026A1
公开(公告)日：2011-04-14
申请号：US12843225
申请日：2010-07-26
申请人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395 , C07H21/00 , C07K16/00 , A61P11/06 , A61P37/02 , C12N5/10 , C12P21/02 , C12N15/63 , C12N1/00
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译： 与IL-13Rα1结合的抗体，抑制IL-13生物活性并包含可变重链和可变轻链的抗体，其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO：1,3,5,7或9可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US07807158B2
公开(公告)日：2010-10-05
申请号：US11325197
申请日：2006-01-03
申请人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Elena Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Thomas Regula , Ralf Schumacher , Stefan Seeber , Jan Olaf Stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： The instant specification discloses an antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
摘要翻译： 本说明书公开了结合IL-13Rα1的抗体，抑制IL-13生物活性并包含可变重链和可变轻链，其特征在于该抗体的可变重链氨基酸序列CDR3选自 SEQ ID NO：1,3,5,7或9的重链CDR3序列，该抗体可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US20060263356A1
公开(公告)日：2006-11-23
申请号：US11325197
申请日：2006-01-03
申请人： Josef Endl , Maria Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Regula , Ralf Schumacher , Stefan Seeber , Jan stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
发明人： Josef Endl , Maria Fuentes , Yvo Graus , Adelbert Grossmann , Sebastian Neumann , Paul Parren , Frank Rebers , Joerg Regula , Ralf Schumacher , Stefan Seeber , Jan stracke , Kay-Gunnar Stubenrauch , Jan Van De Winkel , Martine Van Vugt , Sandra Vereecken-Verploegen
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译： 与IL-13Rα1结合的抗体，抑制IL-13生物活性并包含可变重链和可变轻链，其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO：1,3,5,7或9可用于治疗哮喘和过敏性疾病。
-
公开(公告)号：US20130065277A1
公开(公告)日：2013-03-14
申请号：US13515428
申请日：2010-12-17
CPC分类号： C07K16/2866 , C07K16/00 , C07K16/2875 , C07K16/461 , C07K2317/24 , C07K2317/567
摘要： Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.
摘要翻译： 本文报道了用于减少溶液中免疫球蛋白聚集的方法，包括以下步骤：i）比较抗体重链的第四框架区的氨基酸序列与参照或种系序列，并确定一个或多个苏氨酸 残基和/或丝氨酸残基已经被不同的氨基酸残基替代，和ii）通过将交换的苏氨酸残基和/或丝氨酸残基还原回参考或种系序列的苏氨酸或丝氨酸来修饰免疫球蛋白的氨基酸序列，以及 从而减少溶液中免疫球蛋白的聚集。
-
公开(公告)号：US09150641B2
公开(公告)日：2015-10-06
申请号：US13515428
申请日：2010-12-17
CPC分类号： C07K16/2866 , C07K16/00 , C07K16/2875 , C07K16/461 , C07K2317/24 , C07K2317/567
摘要： Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.
摘要翻译： 本文报道了用于减少溶液中免疫球蛋白聚集的方法，包括以下步骤：i）比较抗体重链的第四框架区的氨基酸序列与参照或种系序列，并确定一个或多个苏氨酸 残基和/或丝氨酸残基已经被不同的氨基酸残基替代，和ii）通过将交换的苏氨酸残基和/或丝氨酸残基还原回参考或种系序列的苏氨酸或丝氨酸来修饰免疫球蛋白的氨基酸序列，以及 从而减少溶液中免疫球蛋白的聚集。
-
-
-
-
搜索结果
5 条记录 (耗时 0.047 秒)